BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: CVE:RX
- CUSIP: N/A
- Web: www.biosyent.com
- Market Cap: C$135.79 million
- Outstanding Shares: 14,648,000
- 52 Week Range: C$6.90 - C$9.30
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Annual Revenue: C$19.23 million
- Price / Sales: 7.06
- Book Value: C$1.34 per share
- Price / Book: 6.92
- EBIDTA: C$6.46 million
- Net Margins: 27.55%
- Return on Equity: 33.60%
- Return on Assets: 30.00%
- Average Volume: 6,883 shs.
Frequently Asked Questions for Biosyent (CVE:RX)
What is Biosyent's stock symbol?
Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."
How were Biosyent's earnings last quarter?
Biosyent Inc. (CVE:RX) released its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.02. The firm had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million. Biosyent had a return on equity of 33.60% and a net margin of 27.55%. View Biosyent's Earnings History.
When will Biosyent make its next earnings announcement?
Who are some of Biosyent's key competitors?
Some companies that are related to Biosyent include NYX Gaming Group Ltd (NYX), Victoria Gold Corp (VIT), Copper Mountain Mining Co.. (CMMC), Input Capital Corp (INP), Conifex Timber (CFF), BSM Technologies (GPS), Titanium Co. (TIC), Orezone Gold Corp (ORE), Madalena Energy (MVN), Strategic Oil & Gas Ltd (SOG), Pan Orient Energy Corp. (POE), Canamax Energy Ltd (CAC), Atico Mining Corp (ATY), Mosaic Capital Corp (M), Ikkuma Resources Corp (IKM), Luna Gold Corp (LGC), Atacama Pacific Gold (ATM) and Africa Energy Corp (AFE).
Who are Biosyent's key executives?
Biosyent's management team includes the folowing people:
- Rene C. Goehrum, Chairman of the Board, President, Chief Executive Officer
- Alfred D'Souza, Chief Financial Officer
- Kevin Wilson, Vice President - Sales and Marketing of BioSyent Pharma Inc
- Douglas R. Larson, Secretary, Director
- Peter D. Lockhard, Independent Director
- Paul R. Montador, Independent Director
- Milton E. Wakefield, Independent Director
- Stephen Wilton, Independent Director
How do I buy Biosyent stock?
Shares of Biosyent and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Biosyent's stock price today?
MarketBeat Community Rating for Biosyent (CVE RX)MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Biosyent stock can currently be purchased for approximately C$9.27.
Consensus Ratings for Biosyent (CVE:RX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Biosyent (CVE:RX)
(Data available from 9/26/2015 forward)
|2/13/2017||Bloom Burton||Reiterated Rating||Accumulate|
Earnings History for Biosyent (CVE:RX)Earnings History by Quarter for Biosyent (CVE RX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/22/2017|| || || || || || || || |
|5/25/2017||Q1 2017||C$0.08||C$0.06||C$4.80 million||C$3.82 million||View||N/A|
Earnings Estimates for Biosyent (CVE:RX)
2017 EPS Consensus Estimate: $0.34
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biosyent (CVE:RX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biosyent (CVE:RX)Insider Trades by Quarter for Biosyent (CVE:RX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/18/2017||Douglas Robert Larson||Director||Sell||1,300||C$9.25||C$12,025.00|
|9/15/2017||Douglas Robert Larson||Director||Sell||200||C$9.25||C$1,850.00|
|9/14/2017||Douglas Robert Larson||Director||Sell||1,500||C$9.20||C$13,800.00|
|6/21/2017||Douglas Robert Larson||Director||Sell||1,000||C$8.10||C$8,100.00|
|6/19/2017||Douglas Robert Larson||Director||Sell||100||C$8.05||C$805.00|
|6/12/2017||Douglas Robert Larson||Director||Sell||200||C$8.05||C$1,610.00|
|3/31/2017||Douglas Robert Larson||Director||Sell||900||C$7.75||C$6,975.00|
|9/8/2016||Douglas Robert Larson||Director||Sell||800||C$8.35||C$6,680.00|
Headline Trends for Biosyent (CVE:RX)
Latest Headlines for Biosyent (CVE:RX)
Biosyent (RX) Chart for Tuesday, September, 26, 2017